RSS-Feed abonnieren
DOI: 10.1055/s-0035-1569974
Herzinsuffizienz und Vorhofflimmern
Publikationsverlauf
Publikationsdatum:
08. März 2016 (online)
![](https://www.thieme-connect.de/media/kardiologie-u2d/201601/lookinside/thumbnails/377_10-1055-s-0035-1569974-1.jpg)
Abstract
Heart failure and atrial fibrillation are two inter-related conditions with similar risk factors and pathophysiology. They both increase morbidity and mortality. Almost all patients need rate control, preferentially with a beta blocker. The role of rhythm control in atrial fibrillation patients with heart failure is unclear. Class I antiarrhythmic agents and dronedarone are contraindicated in patients with heart failure. Amiodarone is an option, however, a major limitation is frequent side effects. Smaller studies demonstrating that catheter ablation of atrial fibrillation may play a role have been published. However, larger studies demonstrating beneficial effects on mortality are yet not available. Antithrombotic therapy is needed in almost all patients to prevent thromboembolic complications.
Therapy of atrial fibrillation in patients with heart failure is a challenge. Therapeutic decisions should be made on an individual patient basis and implies a careful benefit-risk assessment.
-
Herzinsuffizienz und Vorhofflimmern sind beide ausgesprochen häufige Krankheitsbilder. Im Vergleich zum isolierten Auftreten sind die Morbidität und Sterblichkeit deutlich höher, wenn beide Erkrankungen gemeinsam vorliegen. Ob eine Herzinsuffizienz mit reduzierter oder erhaltener Auswurffraktion vorliegt, spielt für die Sterblichkeit keine Rolle.
-
Die Risikofaktoren und Mechanismen, die zur Manifestation einer Herzinsuffizienz und von Vorhofflimmern führen, überschneiden sich – genauso wie das auch für die Präventions- und Behandlungsmaßnahmen gilt.
-
Ein wichtiger Grundpfeiler der Behandlung von Patienten mit Vorhofflimmern bei Herzinsuffizienz ist eine adäquate Frequenzkontrolle. Hierbei steht die Gabe eines Betablockers im Vordergrund, bei unzureichender Frequenzkontrolle kann mit einem Digitalispräparat kombiniert werden.
-
Auch wenn sich Hinweise darauf ergeben, dass ein Sinusrhythmus bei Herzinsuffizienz prognostisch günstiger ist als Vorhofflimmern, ist es bisher nicht gelungen, eindeutig nachzuweisen, dass sich die Prognose mit Maßnahmen verbessert, die den Sinusrhythmus erhalten.
-
Als Antiarrhythmikum steht bei Herzinsuffizienz lediglich Amiodaron zur Verfügung. Das substanzeigene komplexe Nebenwirkungsprofil muss beachtet werden.
-
Große Hoffnungen sind mit der Katheterablation von paroxysmalem Vorhofflimmern bei Herzinsuffizienz verknüpft. Patienten, die der Methode zugeführt werden, sollten sorgfältig ausgewählt werden. Im Vordergrund steht allerdings die Behandlung der auf das Vorhofflimmern bezogenen Symptomatik. Eine Prognoseverbesserung durch Ablation konnte bislang nicht nachgewiesen werden.
-
Bei fast allen Patienten mit Vorhofflimmern bei Herzinsuffizienz besteht eine Indikation zur dauerhaften oralen Antikoagulation. Hierbei haben sich die neuen oralen Antikoagulanzien als wirksam und sicher erwiesen. Ist eine orale Antikoagulation kontraindiziert, kann ein Vorhofohrverschluss erfolgen.
-
Literatur
- 1 Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119: 2516-2525
- 2 Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010; 123: 198-204
- 3 Lubitz SA, Benjamin EJ, Ellinor PT. Atrial Fibrillation in congestive heart failure. Heart failure clinics 2010; 6: 187-200
- 4 Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D
- 5 Camm AJ, Lip GYH, de Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
- 6 January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014; 64: e1-e76
- 7 de Vos CB, Pisters R, Nieuwlaat R et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725-731
- 8 Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269
- 9 Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259
- 10 Lip GY, Heinzel FR, Gaita F et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure. Europace 2015; pii: euv191 [Epub ahead of print]
- 11 Caldwell JC, Mamas MA. Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship. Heart Fail Rev 2012; 17: 27-33
- 12 Lubitz SA, Benjamin EJ, Ellinor PT. Atrial Fibrillation in congestive heart failure. Heart failure clinics 2010; 6: 187-200
- 13 Allessie MA, Boyden PA, Camm AJ et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001; 103: 769-777
- 14 Rivero-Ayerza M, Scholte Op Reimer W et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 2008; 29: 1618-1624
- 15 Shinbane JS, Wood MA, Jensen DN et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29: 709-715
- 16 Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-2925
- 17 Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 2006; 47: 1997-2004
- 18 Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL et al. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail 2012; 5: 191-201
- 19 Melenovsky V, Hay I, Fetics BJ et al. Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J 2005; 26: 705-711
- 20 Boos CJ, Brown L. Anticoagulation in atrial fibrillation and chronic heart failure: the risk and drug of choice. Curr Opin Cardiol 2015; [Epub ahead of print]
- 21 McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2012; 14: 803-869
- 22 Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833
- 23 Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840
- 24 Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513
- 25 Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677
- 26 Mulder BA, Van Veldhuisen DJ, Crijns HJ et al. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail 2013; 15: 1311-1318
- 27 Rienstra M, Damman K, Mulder BA et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1: 21-28
- 28 Wang ZQ, Zhang R, Chen MT et al. Digoxin is associated with increased all-cause mortality in patients with atrial fibrillation regardless of concomitant heart failure: A meta-analysis. J Cardiovasc Pharmacol 2015; 66: 270-275
- 29 Chatterjee NA, Upadhyay GA, Ellenbogen KA et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012; 5: 68-76
- 30 Ganesan AN, Brooks AG, Roberts-Thomson KC et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 2012; 59: 719-726
- 31 Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology . Eur Heart J 2000; 21: 1216-1231
- 32 Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol 2012; 33: 171-257
- 33 Hsu LF, Jaïs P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383
- 34 Ganesan AN, Nandal S, Lüker J et al. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ 2014; 1443-9506
- 35 Boldt LH, Rolf S, Huemer M et al. Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Am Heart J 2008; 155: 890-895
- 36 Jang SJ, Kim MS, Park HJ et al. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 2013; 99: 17-21
- 37 Pokorney SD, Simon DN, Thomas L et al. Investigators Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J 2015; 170: 141-148
- 38 Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507
- 39 Holmes Jr DR, Doshi SK, Kar S et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015; 65: 2614-2623
- 40 Yan P, Dong P, Li Z et al. Statin therapy decreased the recurrence frequency of atrial fibrillation after electrical cardioversion: a meta-analysis. Med Sci Monit 2014; 20: 2753-2758
- 41 Cowie MR, Woehrle H, Wegscheider K et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 2015; 373: 1095-1105